|Day Low/High||38.91 / 39.20|
|52 Wk Low/High||32.69 / 41.77|
AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two...
With newly approved Calquence in hand, AstraZenca is set to compete against J&J-AbbVie's Inbruvica first on mantle cell lymphoma but down the road the challenge could be on more common blood cancers.
The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
Powerhouse performances from Caterpillar and 3M inspire a Dow rally, leading the index to new all-time highs in its 54th record close of the year.
Better-than-expected earnings from a number of key Dow components sweep markets higher.
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BYDUREON ® BCise™ (exenatide extended-release) injectable suspension, a new formulation of BYDUREON ® (exenatide...
AstraZeneca today announced new results of a study that investigated respiratory syncytial virus (RSV) hospitalization risk and costs during the 2014-2016 RSV seasons compared to the 2012-2014 RSV seasons.
AstraZeneca and Merck & Co., Inc.
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for IMFINZI ® ...
The Burlington, Mass.-based pharmaceutical firm on Oct. 6 secured approval from the Food and Drug Administration for its osteoarthritis knee pain treatment Zilretta, a non-opioid medicine.
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for TAGRISSO ® (osimertinib) for the 1st-line treatment of patients with metastatic...
Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.
Here's what you need to know now for Monday, Oct. 2.
Newly public companies such as Roku, NuCana and Restoration Robotics could bring a jolt to your portfolio. But remember all IPOs aren't created equally.
So far in 2017, we have had to say farewell to many CEOs, including these.
AstraZeneca today announced full results from the EXSCEL ( EX enatide S tudy of C ardiovascular E vent L owering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in...
Wall Street starts the week with a rally.
The Dow is up more than 250 points.
The world's biggest generic drug maker Monday named Kare Schultz as president and CEO, ending months of speculation about who would replace former head Erez Vigodman, who left the company in February for undisclosed reasons.
AstraZencea shares topped London's FTSE 100 Monday after better-than-expected results in a key lung cancer treatment trial.
AstraZeneca and MedImmune, its global biologics research and development arm, today announced the full progression-free survival (PFS) data from a planned interim analysis of the investigational Phase III PACIFIC trial.
AstraZeneca today announced the full results of the Phase III FLAURA trial, which support TAGRISSO ®'s (osimertinib) clear potential as a new standard of care (SoC) in the 1st-line treatment of adult patients with...
Cellect Biomd was up after securing orphan drug status for its transplant anti-rejection drug.
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved FASLODEX ® (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor positive (HR+), human epidermal...
AstraZeneca and Merck & Co., Inc.
The drug would be the first such treatment in Europe.
One of the hottest biotech stocks of the last month is selling off.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.